Carbon22 Receives FDA 510(k) Clearance for FusionFrame™ Ring Lock System

Carbon22 Consortium designed circular external fixator can treat complex foot and ankle deformities as well as provide a static frame for various indications.

Carbon22, a GLW, Inc. company, (“Carbon22”) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new FusionFrame™ Ring Lock System, a circular external fixator. This versatile system was designed to be simple-to-use with a wide range of assembly components. FusionFrame™ was developed in part in collaboration with the Carbon22 Consortium, a select group of orthopedic and podiatric surgeons.

The unique design ensures circumferential access for precise fixation and can address a variety of indications in a straightforward and cost-effective manner. Multi-level constructs may be built to target the zone of pathology or apex of a deformity.

Axel Cremer, Chief Technology Officer for Carbon22, stated, “The 510(k) clearance for our FusionFrame™ Ring Lock System is an exciting milestone for Carbon22. Our world class team has done an excellent job of expanding our circular external fixator technology platform and building on the clinical success of the existing Ring Lock System. We’re excited to launch the FusionFrame™ Ring Lock System and look forward to introducing future variations which are currently in development.”

The FusionFrame™ Ring Lock System represents next-level functionality, utilizes state-of-the-art materials, and boasts an unparalleled design that provides the ability to customize frames specific to patient needs. This system can treat complex foot and ankle deformities, as well as provide a static frame for various indications.

“As we continue to develop our new, innovative patent-pending technology platforms, designed to allow for visualization of fusion sites (intraoperatively) and post-operative healing zones, we are working to ensure that foot and ankle surgeons have the right devices they need to treat today’s foot and ankle conditions,“ said Thomas H. Lee MD, Chief Medical Officer for Carbon22.

About Carbon22, a GLW Inc. company
Carbon22 is a privately held company, focused on the design and development of cost-effective, high-margin implant and instrument solutions for various musculoskeletal foot & ankle applications. Carbon22 and its products are commercialized in the US market through exclusive distribution and education agreements with Novastep, Inc.